In the present study, we evaluated TRIP13 as a potential therapeutic target by treating a panel of CRC cells exhibiting various molecular alterations in p53, KRAS, BRAF, EGFR and MSI, and xenograft models with DCZ0415, and showed that DCZ0415 inhibits CRC cell proliferation and tumour growth and progression. This evidence concerns the gene BRAF and colorectal carcinoma.